Xinshubao tablet rescues cognitive dysfunction in a mouse model of vascular dementia: Involvement of neurogenesis and neuroinflammation

Biomed Pharmacother. 2024 Mar:172:116219. doi: 10.1016/j.biopha.2024.116219. Epub 2024 Feb 3.

Abstract

Vascular dementia (VaD) represents a severe cognitive dysfunction syndrome closed linked to cardiovascular function. In the present study, we assessed the potential of Xinshubao tablet (XSB), a traditional Chinese prescription widely used for cardiovascular diseases, to mitigate neuropathological damage in a mouse model of VaD and elucidated the underlying mechanisms. Our findings revealed that oral administration of XSB rescued the cardiac dysfunction resulting from bilateral common carotid artery stenosis (BCAS), improved the cerebral blood flow (CBF) and cognitive function, reduced white matter injury, inhibited excessive microglial and astrocytic activation, stimulated hippocampal neurogenesis, and reduced neural apoptosis in the brains of BCAS mice. Mechanistically, RNA-seq analysis indicated that XSB treatment was significantly associated with neuroinflammation, vasculature development, and synaptic transmission, which were further confirmed by q-PCR assays. Western blot results revealed that XSB treatment hindered the nuclear translocation of nuclear factor-κB (NF-κB), thereby suppressing the NF-κB signaling pathway. These results collectively demonstrated that XSB could ameliorate cognitive dysfunction caused by BCAS through regulating CBF, reducing white matter lesions, suppressing glial activation, promoting neurogenesis, and mitigating neuroinflammation. Notably, the NF-κB signaling pathway emerged as a pivotal player in this mechanism.

Keywords: Chronic cerebral hypoperfusion; NF-κB signaling pathway; Neurogenesis; Vascular dementia; White matter damage; Xinshubao tablet.

MeSH terms

  • Animals
  • Carotid Stenosis*
  • Cognitive Dysfunction* / drug therapy
  • Dementia, Vascular* / drug therapy
  • Disease Models, Animal
  • Mice
  • NF-kappa B
  • Neurogenesis
  • Neuroinflammatory Diseases

Substances

  • NF-kappa B